{
    "nct_id": "NCT05765734",
    "official_title": "A Phase 1/2 Study of TAS3351 in Patients With Advanced Non-Small Cell Lung Cancer and EGFR Mutations",
    "inclusion_criteria": "* Locally advanced, non-resectable or metastatic NSCLC\n* Have adequate organ function\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Has tumor tissue available to allow for analysis of EGFRmt status\n\nDose Escalation:\n\nâ€¢ Has any EGFRmt status\n\nDose Escalation back-fill part, Dose Expansion and Phase II:\n\n* Has any sensitizing EGFRmt and a confirmed C797S EGFRmt\n* Has measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participating in medical research not compatible with this study\n* Symptomatic and unstable CNS metastases\n* Have not recovered from prior cancer treatment\n* Have a significant cardiac condition\n* Are a pregnant or breastfeeding female\n* A serious illness or medical condition\n* Unable to swallow or digest pills",
    "miscellaneous_criteria": ""
}